Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Asia Pac J Ophthalmol (Phila). 2022 Sep 1;11(5):441-452. doi: 10.1097/APO.0000000000000557.
Keratoconus is a progressive corneal thinning disorder that can lead to vision loss. In the last 2 decades, corneal crosslinking (CXL) has emerged as an effective method to halt the progression of keratoconus and reduce the number of patients requiring keratoplasty. The procedure has been adopted globally and has evolved to become a part of combination treatments to regularize the cornea and improve visual outcomes. CXL has even been extrapolated in managing other ocular pathologies such as progressive myopia, infectious keratitis, and bullous keratopathy. This review aims to summarize the current role of CXL in keratoconus and its alternative uses, and provide insights into future developments in this fast-developing field.
圆锥角膜是一种进行性角膜变薄的疾病,可导致视力丧失。在过去的 20 年中,角膜交联术(CXL)已成为阻止圆锥角膜进展和减少需要角膜移植手术的患者数量的有效方法。该手术已在全球范围内采用,并已发展成为角膜矫正和改善视觉效果的联合治疗方法的一部分。CXL 甚至已被扩展用于治疗其他眼部疾病,如进行性近视、感染性角膜炎和大疱性角膜病变。本综述旨在总结 CXL 在圆锥角膜中的当前作用及其其他用途,并为这一快速发展领域的未来发展提供见解。